Furthermore, the evidence for this signaling axis is found in the TCGA for pancreatic cancer, where CDCP1 and all four identified integrins show significantly elevated mRNA levels in cancers with RAS mutations. This evidence concerns the gene CDCP1 and familial pancreatic carcinoma.